Latest news with #Celecoxib
Business Standard
16-07-2025
- Business
- Business Standard
Stock Alert: ICICI Lombard, HDB Financial, HDFC Life, Zydus Lifesciences
Securities in F&O Ban:Glenmark Pharmaceuticals, Hindustan Copper and RBL Bank shares banned from F&O Trading on 16 July Results:Tech Mahindra, ITC Hotels, Angel One, D B Corp, Le Travenues Tech, Kalpataru, and L&T Technology Services will declare their results later to Watch:ICICI Lombard General Insurance Company reported a 28.7% jump in standalone net profit 747.08 crore on 14.3% increase in total income to Rs 6,408.54 crore in Q1 FY26 over Q1 Life Insurance Companys standalone net profit jumped 14.4% to Rs 546.46 crore on 9.5% increase in total income to Rs 29,521.77 crore in Q1 FY26 over Q1 Dials consolidated net profit climbed 38.4% to Rs 115.74 crore on 16.2% jump in net sales to Rs 270.27 crore in Q1 June 2025 over Q1 June 2024. Arisinfra Solutions has signed memorandum of undertaking (MoU) with Wadhwa Construction and Infrastructure, to supply materials for a development of 7 new towers totalling to a 1.2 million sq. ft. of construction area. This extension is expected to contribute an additional Rs 75 crore to Arisinfras material supplies over the next 36 to 40 Financial Services consolidated net profit declined 19.1% to Rs 530.90 crore despite a 16.3% increase in total income to Rs 4,266.10 crore in Q1 FY26 compared with Q1 FY25. Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID).Powered by Capital Market - Live News
Time of India
16-07-2025
- Business
- Time of India
Zydus Lifesciences shares in focus after USFDA nod for Celecoxib capsules
Zydus Lifesciences shares will be in focus after the company received final approval from the United States Food and Drug Administration ( USFDA ) for its Celecoxib capsules , a medication used for pain management. The approval covers Celecoxib capsules in strengths of 50 mg, 100 mg, 200 mg, and 400 mg, the company said in a regulatory filing on Tuesday. The drug will be manufactured at Zydus Lifesciences' facility in Ahmedabad. Celecoxib, sold under the brand name Celebrex, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation caused by conditions such as arthritis, ankylosing spondylitis, menstrual pain, and juvenile rheumatoid arthritis in children aged two years and above. According to IQVIA data, Celecoxib capsules recorded sales of $122.6 million in the US for the 12 months ending May 2025. With this approval, Zydus now has 428 ANDA approvals and has filed a total of 492 since it began the process in FY2003-04. Live Events In June, the USFDA issued two observations following an inspection conducted between June 9 and 18 at the company's oncology injectable manufacturing facility at SEZ 1 near Matoda, Ahmedabad. Zydus Lifesciences shares target price According to Trendlyne, the average target price for Zydus Lifesciences shares stands at Rs 967, indicating a potential downside of 1% from current levels. Of the 30 analysts tracking the stock, most have maintained a 'Hold' rating. Zydus Lifesciences shares performance Zydus Lifesciences shares are down 19% over the past year but have gained 63% over the last two years. The company's current market capitalisation is Rs 97,317 crore. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Economic Times
16-07-2025
- Business
- Economic Times
Zydus Lifesciences shares in focus after USFDA nod for Celecoxib capsules
Zydus Lifesciences shares will be in focus after the company received final approval from the United States Food and Drug Administration (USFDA) for its Celecoxib capsules, a medication used for pain management. ADVERTISEMENT The approval covers Celecoxib capsules in strengths of 50 mg, 100 mg, 200 mg, and 400 mg, the company said in a regulatory filing on Tuesday. The drug will be manufactured at Zydus Lifesciences' facility in Ahmedabad. Celecoxib, sold under the brand name Celebrex, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation caused by conditions such as arthritis, ankylosing spondylitis, menstrual pain, and juvenile rheumatoid arthritis in children aged two years and above. According to IQVIA data, Celecoxib capsules recorded sales of $122.6 million in the US for the 12 months ending May this approval, Zydus now has 428 ANDA approvals and has filed a total of 492 since it began the process in June, the USFDA issued two observations following an inspection conducted between June 9 and 18 at the company's oncology injectable manufacturing facility at SEZ 1 near Matoda, Ahmedabad. ADVERTISEMENT According to Trendlyne, the average target price for Zydus Lifesciences shares stands at Rs 967, indicating a potential downside of 1% from current levels. Of the 30 analysts tracking the stock, most have maintained a 'Hold' rating. ADVERTISEMENT Zydus Lifesciences shares are down 19% over the past year but have gained 63% over the last two years. The company's current market capitalisation is Rs 97,317 crore. (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times) ADVERTISEMENT (You can now subscribe to our ETMarkets WhatsApp channel)
Time of India
16-07-2025
- Business
- Time of India
Stocks in news: HDFC Life, HDB Financial, Tech Mahindra, Dixon Tech, ITC Hotels
Markets witnessed some respite on Tuesday and edged marginally higher after four consecutive sessions of decline. In today's trade, shares of HDFC Life , HDB Financial , Tech Mahindra , Dixon Tech, ITC Hotels among others will be in focus due to various news developments and first quarter results. Tech Mahindra, ITC Hotels, LTTS, Angel One Shares of Tech Mahindra , ITC Hotels, LTTS and Angel One will be in focus as the companies will be in focus due to various news developments. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo HDB Financial HDB Financial Services reported a marginal decline in net profit for the first quarter of FY26, with profit after tax coming in at Rs 568 crore. It was down 2% from Rs 582 crore in the same quarter last year. HDFC Life HDFC Life reported a 14% growth in its Q1FY26 standalone net profit at Rs 546 crore versus Rs 478 crore in the year ago period. Just Dial Just Dial's net profit was up 13% to Rs 160 crore in the first quarter, while revenue rose 6% to Rs 298 crore in the same period. Live Events Dixon Technologies Dixon Technologies has entered into a binding term sheet to acquire a 51% stake in Kunshan Q Tech Microelectronics. Kotak Mahindra Bank Phani Shankar resigned as the President and Chief Credit Officer effective July 21. Zydus Life Zydus Life received final approval From USFDA for Celecoxib Capsules. These are used to treat pain or inflammation caused by many conditions such as Arthritis.
&w=3840&q=100)
Business Standard
15-07-2025
- Business
- Business Standard
Zydus Lifesciences gets USFDA nod for its painkiller Celecoxib capsules
Zydus Lifesciences on Tuesday announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its painkiller medicine capsule named Celebrex (Celecoxib capsules). The company said that the medicine is used to treat pain or inflammation caused by many conditions such as arthritis, ankylosing spondylitis, and menstrual pain, along with juvenile rheumatoid arthritis in children who are at least 2 years old. The capsules will be produced at Zydus Lifesciences Ltd, Ahmedabad. Celecoxib capsules had sales of $122.6 million in the US in the 12-month period ending May 2025. The clearance is important as earlier this year, the company came under scrutiny following surveillance inspections at its Gujarat facility by the USFDA. Later, the company said in a regulatory filing to NSE that 'the inspection concluded with six observations and none of them were related to data integrity." The company reported in May that its consolidated net profit slipped about 1 per cent year-on-year (Y-o-Y) to ₹1,171 crore in the March quarter of financial year 2025 (Q4FY25); however, revenue soared 18 per cent Y-o-Y to ₹6,527.9 crore. The company is yet to file its earnings report for the first quarter of FY26.
